Niagen Bioscience (NAGE) EBT Margin (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly EBT Margin of 21.4% for Q1 2026, up 424.0% year-over-year from 4.08% in Q1 2025, and up 63.68% quarter-over-quarter from 13.07% in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) EBT Margin (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported EBT Margin for 17 consecutive years, with 21.4% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 424.0% year-over-year to 21.4%; the TTM figure through Mar 2026 stood at 15.1% (up 159.0% YoY), while the FY2025 annual figure was 14.06%, up 517.0% from the prior year.
- EBT Margin improved to 21.4% in Q1 2026 per NAGE's latest filing, from 13.07% in the prior quarter.
- Across five years, EBT Margin topped out at 25.7% in Q4 2024 and bottomed at 69.67% in Q2 2022.
- Historically, EBT Margin has averaged 9.17% across 5 years, with a median of 1.27% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin sank 1495 bps — and 2023, when it soared 3624 bps.
- Niagen Bioscience's EBT Margin stood at 7.52% in 2022, then surged by 83 bps to 1.27% in 2023, then soared by 2117 bps to 25.7% in 2024, then sank by 49 bps to 13.07% in 2025, then soared by 64 bps to 21.4% in 2026.
- Business Quant data shows NAGE's EBT Margin at 21.4% in Q1 2026, 13.07% in Q4 2025, and 14.12% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | 3.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.59% |
| Mar 31, 2026 | 21.40% |
| Dec 31, 2025 | 13.07% |
| Sep 30, 2025 | 14.12% |
| Jun 30, 2025 | 12.01% |
| Mar 31, 2025 | 17.16% |
| Dec 31, 2024 | 25.70% |
| Sep 30, 2024 | 7.34% |
| Jun 30, 2024 | -0.07% |
| Mar 31, 2024 | -2.22% |
| Dec 31, 2023 | 0.54% |
| Sep 30, 2023 | -4.92% |
| Jun 30, 2023 | -10.78% |
| Mar 31, 2023 | -8.72% |
| Dec 31, 2022 | -6.88% |
| Sep 30, 2022 | -17.99% |
| Jun 30, 2022 | -38.23% |
| Mar 31, 2022 | -44.85% |
| Dec 31, 2021 | -29.98% |
| Sep 30, 2021 | -51.17% |